.Monopar Rehabs is bouncing back a medicine coming from the dump of AstraZeneca’s unusual disease pipeline. It has actually licensed ALXN-1840, a prospect for the
Read moreAN 2 halves head count, stops period 3 test after records let down
.AN2 Therapeutics is reviewing its business in feedback to lackluster midphase records, promising to lay off half its workers and stop a stage 3 research
Read moreALX’s fizzling CD47 action fee delivers stock spiraling down
.ALX Oncology’s period 2 stomach cancer feedback rate has deteriorated. After viewing its own CD47 blocker simply beat command over the 1st fifty percent of
Read moreAC Immune sees ‘spots’ potential in Alzheimer’s drug information
.After much more than 20 years of focus on neurodegenerative diseases, Swiss biotech hvac Invulnerable claims it might possess a game changer on its hands.The
Read more